{"Clinical Trial ID": "NCT02162667", "Intervention": ["INTERVENTION 1:", "- TC-P6", "The patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on day 1 of Cycle 1, followed by 6 mg/kg on day 1 of Cycles 2 to 8 (three-week cycles). Patients also received docetaxel 75 mg/m^2 during Cycles 1 to 4 and FEC (fluorouracil 500mg/m^2, epirubin 75mg/m^2 and cyclophosphamide 500mg/m^2) during Cycles 5 to 8. After a total of 8 cycles of neoadjuvant treatment, surgery was performed within 3-6 weeks of the last study dose.", "INTERVENTION 2:", "- Herceptin", "The patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on day 1 of Cycle 1, followed by 6 mg/kg on day 1 of Cycles 2 to 8 (cycles 3 weeks), as well as docetaxel 75 mg/m^2 in Cycles 1 to 4 and FEC (fluorouracil 500 mg/m^2, epirubin 75 mg/m^2 and cyclophosphamide 500 mg/m^2) in Cycles 5 to 8. After a total of 8 cycles of neoadjuvant treatment, surgery was performed within 3-6 weeks of the last study dose."], "Eligibility": ["Incorporation criteria:", "A patient with confirmed and newly diagnosed breast cancer", "* Patients with operational breast cancer at clinical stage I, II or IIIa according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th Edition", "A patient with locally confirmed positive HER2 status, defined as a 3+ score by IHC (immunohistochemistry).", "- Exclusion criteria:", "Patients with bilateral breast cancer", "* Patients who have received prior treatment for breast cancer, including chemotherapy, biological therapy, hormone therapy, immunotherapy, radiotherapy or surgery, including any previous treatment with anthracyclines."], "Results": ["Performance measures:", "The percentage of patients with a complete pathological response defined as the absence of invasive tumour cells in the breast and axillary lymph nodes, regardless of the ductal carcinoma in situ (CDIS)", "The patient who has undergone the neoadjuvant period completely (24 weeks) will be operated within 3 to 6 weeks of the last treatment of the neoadjuvant period.", "The primary endpoint, the complete pathological response, will be evaluated using resequent bio-specmens collected from the breast and axilla during surgery.", "Delay: After neo-adjuvant treatment and surgery (up to 30 weeks)", "Results 1:", "Title of arm/group: CT-P6", "The patient received CT-P6 at an initial dose of 8 mg/kg administered by a single IV infusion on day 1 of Cycle 1, followed by 6 mg/kg on day 1 of Cycles 2 to 8 (cycles 3 weeks), as well as docetaxel 75 mg/m^2 in Cycles 1 to 4 and FEC (fluorouracil 500mg/m^2, epirubin 75mg/m^2 and cyclophosphamide 500mg/m^2) in Cycles 5 to 8. After a total of 8 cycles of neoadjuvant treatment, surgery was performed within 3-6 weeks of the last study dose.", "Total number of participants analysed: 248", "Type of measurement: Number", "Unit of measure: percentage of respondents 46.77 (40.43 to 53.19)", "Results 2:", "Title of the arm/group: Herceptin", "The patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on day 1 of Cycle 1, followed by 6 mg/kg on day 1 of Cycles 2 to 8 (cycles 3 weeks), as well as docetaxel 75 mg/m^2 during Cycles 1 to 4 and FEC (fluorouracil 500mg/m^2, epirubin 75mg/m^2 and cyclophosphamide 500mg/m^2) during Cycles 5 to 8. After a total of 8 cycles of neoadjuvant treatment, surgery was performed within 3-6 weeks of the last study dose.", "Total number of participants analysed: 256", "Type of measurement: Number", "Unit of measure: percentage of respondents 50.39 (44.10 to 56.68)"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/271 (8.12 per cent)", "Anemia1/271 (0.37%)", "Febrile neutropenia6/271 (2.21 per cent)", "- Leucocytosis0,271 (0.00 %)", "- Neutropenia2/271 (0.74%)", "- Acute myocardial infarction0,271 (0.00 %)", "Adams-Stokes syndrome1/271 (0.37%)", "Angine pectoris0.271 (0.00 %)", "Congestive cardiomyopathy0.271 (0.00 %)", "Myocardial infarction0,271 (0.00 %)", "Dacryostenosis acquired0,271 (0.00 %)", "Adverse Events 2:", "Total: 36/278 (12.95%)", "Anemia3/278 (1.08%)", "\u2022 Febrile neutropenia3/278 (1.08 %)", "- Leucocytosis1/278 (0.36%)", "Neutropenia3/278 (1.08%)", "Acute myocardial infarction1/278 (0.36%)", "Adams-Stokes syndrome/278 (0.00 %)", "Angine pectoris1/278 (0.36%)", "Congestive cardiomyopathy1/278 (0.36%)", "Myocardial infarction1/278 (0.36%)", "Dacryostenosis acquired1/278 (0.36%)"]}